Positive News SentimentPositive NewsNASDAQ:ZLAB Zai Lab (ZLAB) Stock Forecast, Price & News $24.31 +0.31 (+1.29%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$24.15▼$24.7950-Day Range$22.72▼$31.4952-Week Range$20.98▼$49.81Volume288,160 shsAverage Volume366,223 shsMarket Capitalization$2.40 billionP/E RatioN/ADividend YieldN/APrice Target$83.10 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Zai Lab MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside241.8% Upside$83.10 Price TargetShort InterestBearish3.40% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.75) to ($2.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.92 out of 5 starsMedical Sector700th out of 972 stocksPharmaceutical Preparations Industry325th out of 445 stocks 3.5 Analyst's Opinion Consensus RatingZai Lab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $83.10, Zai Lab has a forecasted upside of 241.8% from its current price of $24.31.Amount of Analyst CoverageZai Lab has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.40% of the outstanding shares of Zai Lab have been sold short.Short Interest Ratio / Days to CoverZai Lab has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Zai Lab has recently increased by 2.44%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldZai Lab does not currently pay a dividend.Dividend GrowthZai Lab does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZLAB. Previous Next 2.7 News and Social Media Coverage News SentimentZai Lab has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Zai Lab this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for ZLAB on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Zai Lab to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zai Lab insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.23% of the stock of Zai Lab is held by insiders.Percentage Held by Institutions43.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zai Lab are expected to grow in the coming year, from ($3.75) to ($2.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zai Lab is -5.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zai Lab is -5.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZai Lab has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Zai Lab (NASDAQ:ZLAB) StockZai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.Read More ZLAB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZLAB Stock News HeadlinesSeptember 18, 2023 | finance.yahoo.comZai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in ChinaSeptember 7, 2023 | seekingalpha.comZai Lab Stock: De-Risking Through Market TappingOctober 1, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 5, 2023 | msn.comRebel's Edge - September 5: $ABNB, $MANU, $ZLAB, and Royce Lewis hits 3 Grand-Slams In 8 GamesSeptember 5, 2023 | markets.businessinsider.comPre-market Movers: HSDT, UPTD, ADTX, RENB, MLGO…September 5, 2023 | msn.comZai Lab (NASDAQ:ZLAB) Soars 12% on Breakthrough Therapy Designation for Repotrectinib in ChinaAugust 31, 2023 | finance.yahoo.comZai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology DrugAugust 30, 2023 | finance.yahoo.comZai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in ChinaOctober 1, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.August 10, 2023 | markets.businessinsider.comZai Lab (ZLAB) Receives a Buy from Bank of America SecuritiesAugust 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Technology Companies: Zai Lab (ZLAB) and Kratos Defense (KTOS)August 8, 2023 | seekingalpha.comZai Lab GAAP EPS of -$1.25 misses by $0.50, revenue of $68.86M misses by $1.81MAugust 7, 2023 | finance.yahoo.comZai Lab Announces Second Quarter 2023 Financial Results and Corporate UpdatesAugust 7, 2023 | finance.yahoo.comZai Lab Announces Second Quarter 2023 Financial Results and Corporate UpdatesAugust 3, 2023 | msn.comZai Lab Limited - ADR (ZLAB) Price Target Decreased by 5.82% to 34.24July 27, 2023 | seekingalpha.comZai Lab: LUNAR Trial Paves Way For New TherapiesJuly 20, 2023 | finance.yahoo.comZai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023July 19, 2023 | finance.yahoo.comJAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer PatientsJuly 17, 2023 | msn.comArgenx, Zai Lab Soar on Promising Data in CIDPJuly 17, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on Zai Lab (ZLAB)July 17, 2023 | finance.yahoo.comZai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating PolyneuropathyJuly 14, 2023 | finance.yahoo.comZai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric CancerJuly 12, 2023 | seekingalpha.comZai Lab: Encouraging Developments Amid Ever-Present Geopolitical RiskJuly 10, 2023 | finance.yahoo.comZai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia GravisJuly 6, 2023 | finance.yahoo.comZai Lab Announces Promotion of Yajing Chen to Chief Financial OfficerJuly 6, 2023 | finance.yahoo.comZai Lab Announces Promotion of Yajing Chen to Chief Financial OfficerJuly 1, 2023 | benzinga.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation – ZLABSee More Headlines Receive ZLAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter. Email Address ZLAB Company Calendar Last Earnings8/07/2023Today9/30/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZLAB CUSIPN/A CIK1704292 Webwww.zailaboratory.com Phone862161632588Fax86-21-6163-2570Employees2,036Year FoundedN/APrice Target and Rating Average Stock Price Forecast$83.10 High Stock Price Forecast$130.00 Low Stock Price Forecast$62.50 Forecasted Upside/Downside+241.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($4.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-443,290,000.00 Net Margins-156.07% Pretax Margin-156.07% Return on Equity-38.48% Return on Assets-32.78% Debt Debt-to-Equity RatioN/A Current Ratio7.63 Quick Ratio7.36 Sales & Book Value Annual Sales$215.04 million Price / Sales11.17 Cash FlowN/A Price / Cash FlowN/A Book Value$10.68 per share Price / Book2.28Miscellaneous Outstanding Shares98,840,000Free Float93,670,000Market Cap$2.40 billion OptionableOptionable Beta1.12 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Ying Du Ph.D. (Age 57)Founder, Chairperson & CEO Comp: $1.67MMr. Joshua L. Smiley (Age 53)Pres & COO Comp: $647.11kDr. Rafael G. Amado M.D. (Age 59)Pres and Head of Global Oncology R&D Comp: $477kDr. Harald Reinhart M.D. (Age 71)Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases Comp: $923.33kDr. Yajing Chen Ph.D.Chief Financial OfficerDr. Peter Huang Ph.D.Chief Scientific OfficerMr. Frazor Titus Edmondson III (Age 57)J.D., Chief Legal Officer & Corp. Sec. Ms. Ann E. Beasley J.D.Chief Compliance OfficerDr. Ning Xu M.D. (Age 58)Exec. VP & Head of Clinical Operations Dr. Jonathan J. Wang MBA (Age 41)Ph.D., Chief Bus. Officer More ExecutivesKey CompetitorsXenon PharmaceuticalsNASDAQ:XENEArcellxNASDAQ:ACLXProtagonist TherapeuticsNASDAQ:PTGXREGENXBIONASDAQ:RGNXOmniAbNASDAQ:OABIView All CompetitorsInsiders & InstitutionsTriatomic Management LPBought 13,000 shares on 9/7/2023Ownership: 0.013%Nuveen Asset Management LLCSold 51,080 shares on 8/16/2023Ownership: 0.071%Citadel Advisors LLCBought 5,100 shares on 8/15/2023Ownership: 0.000%Royal Bank of CanadaBought 4,613 shares on 8/15/2023Ownership: 0.005%Walleye Trading LLCSold 4,700 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ZLAB Stock - Frequently Asked Questions Should I buy or sell Zai Lab stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZLAB shares. View ZLAB analyst ratings or view top-rated stocks. What is Zai Lab's stock price forecast for 2023? 3 brokers have issued twelve-month target prices for Zai Lab's stock. Their ZLAB share price forecasts range from $62.50 to $130.00. On average, they anticipate the company's share price to reach $83.10 in the next year. This suggests a possible upside of 241.8% from the stock's current price. View analysts price targets for ZLAB or view top-rated stocks among Wall Street analysts. How have ZLAB shares performed in 2023? Zai Lab's stock was trading at $30.70 at the beginning of the year. Since then, ZLAB stock has decreased by 20.8% and is now trading at $24.31. View the best growth stocks for 2023 here. When is Zai Lab's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our ZLAB earnings forecast. How were Zai Lab's earnings last quarter? Zai Lab Limited (NASDAQ:ZLAB) released its quarterly earnings results on Monday, August, 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by $0.51. The company earned $68.86 million during the quarter, compared to analyst estimates of $71.40 million. Zai Lab had a negative trailing twelve-month return on equity of 38.48% and a negative net margin of 156.07%. What ETFs hold Zai Lab's stock? ETFs with the largest weight of Zai Lab (NASDAQ:ZLAB) stock in their portfolio include Global X China Biotech Innovation ETF (CHB), ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Loncar China Biopharma ETF (CHNA), Fidelity Disruptive Medicine ETF (FMED) and Invesco Golden Dragon China ETF (PGJ) and What guidance has Zai Lab issued on next quarter's earnings? Zai Lab issued an update on its second quarter earnings guidance on Monday, August, 7th. The company provided earnings per share guidance of ($1.25) for the period, compared to the consensus EPS estimate of ($0.79). The company issued revenue guidance of $68.9, compared to the consensus revenue estimate of $70.48 million. What other stocks do shareholders of Zai Lab own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN). When did Zai Lab IPO? (ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO. What is Zai Lab's stock symbol? Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB." How do I buy shares of Zai Lab? Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Zai Lab's stock price today? One share of ZLAB stock can currently be purchased for approximately $24.31. How much money does Zai Lab make? Zai Lab (NASDAQ:ZLAB) has a market capitalization of $2.40 billion and generates $215.04 million in revenue each year. The company earns $-443,290,000.00 in net income (profit) each year or ($4.09) on an earnings per share basis. How many employees does Zai Lab have? The company employs 2,036 workers across the globe. How can I contact Zai Lab? Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The official website for the company is www.zailaboratory.com. The company can be reached via phone at 862161632588, via email at jsteier@burnsmc.com, or via fax at 86-21-6163-2570. This page (NASDAQ:ZLAB) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.